- Home
- BMEA vs BAFN Comparison
BMEA vs BAFN Comparison
Compare BMEA & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- BAFN
- Stock Information
- Founded
- BMEA 2017
- BAFN 1999
- Country
- BMEA United States
- BAFN United States
- Employees
- BMEA N/A
- BAFN N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- BAFN Savings Institutions
- Sector
- BMEA Health Care
- BAFN Finance
- Exchange
- BMEA Nasdaq
- BAFN Nasdaq
- Market Cap
- BMEA 65.8M
- BAFN 65.2M
- IPO Year
- BMEA 2021
- BAFN N/A
- Fundamental
- Price
- BMEA $1.44
- BAFN $16.30
- Analyst Decision
- BMEA Strong Buy
- BAFN
- Analyst Count
- BMEA 11
- BAFN 0
- Target Price
- BMEA $27.60
- BAFN N/A
- AVG Volume (30 Days)
- BMEA 703.1K
- BAFN 6.6K
- Earning Date
- BMEA 05-05-2025
- BAFN 07-24-2025
- Dividend Yield
- BMEA N/A
- BAFN 1.96%
- EPS Growth
- BMEA N/A
- BAFN 113.18
- EPS
- BMEA N/A
- BAFN 2.34
- Revenue
- BMEA N/A
- BAFN $80,167,000.00
- Revenue This Year
- BMEA N/A
- BAFN N/A
- Revenue Next Year
- BMEA N/A
- BAFN N/A
- P/E Ratio
- BMEA N/A
- BAFN $6.97
- Revenue Growth
- BMEA N/A
- BAFN 2.60
- 52 Week Low
- BMEA $1.29
- BAFN $11.00
- 52 Week High
- BMEA $13.07
- BAFN $19.75
- Technical
- Relative Strength Index (RSI)
- BMEA 39.69
- BAFN 60.32
- Support Level
- BMEA $1.29
- BAFN $14.79
- Resistance Level
- BMEA $1.52
- BAFN $15.51
- Average True Range (ATR)
- BMEA 0.14
- BAFN 0.45
- MACD
- BMEA 0.01
- BAFN 0.11
- Stochastic Oscillator
- BMEA 28.17
- BAFN 97.30
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.